Selected article for: "acute ards respiratory distress syndrome and admission syndrome"

Author: Convertino, Irma; Tuccori, Marco; Ferraro, Sara; Valdiserra, Giulia; Cappello, Emiliano; Focosi, Daniele; Blandizzi, Corrado
Title: Exploring pharmacological approaches for managing cytokine storm associated with pneumonia and acute respiratory distress syndrome in COVID-19 patients
  • Cord-id: 1ru15s5a
  • Document date: 2020_6_11
  • ID: 1ru15s5a
    Snippet: Sars-CoV-2 complications include pneumonia and acute respiratory distress syndrome (ARDS), which require intensive care unit admission. These conditions have rapidly overwhelmed healthcare systems, with detrimental effects on the quality of care and increased mortality. Social isolation strategies have been implemented worldwide with the aim of reducing hospital pressure. Among therapeutic strategies, the use of immunomodulating drugs, to improve prognosis, seems promising. Particularly, since p
    Document: Sars-CoV-2 complications include pneumonia and acute respiratory distress syndrome (ARDS), which require intensive care unit admission. These conditions have rapidly overwhelmed healthcare systems, with detrimental effects on the quality of care and increased mortality. Social isolation strategies have been implemented worldwide with the aim of reducing hospital pressure. Among therapeutic strategies, the use of immunomodulating drugs, to improve prognosis, seems promising. Particularly, since pneumonia and ARDS are associated with a cytokine storm, drugs belonging to therapeutic classes as anti-IL-6, anti-TNF, and JAK inhibitors are currently studied. In this article, we discuss the potential advantages of the most promising pharmacological approaches.

    Search related documents:
    Co phrase search for related documents
    • action mechanism and adalimumab infliximab: 1
    • action mechanism and adalimumab infliximab etanercept: 1
    • action mechanism and administration route: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • action mechanism and lymphocyte activation: 1, 2, 3
    • adalimumab clinical trial and low immunogenicity: 1
    • administration route and low immunogenicity: 1, 2, 3
    • administration route and lung detect: 1